Kidney disease supplements: what to stop, keep or watch
Updated: 4 hours ago
The short answer
A supplement decision depends on the ingredient, dose, kidney function, medicines and lab results. Your eGFR, the filtering estimate on your blood panel, helps guide that discussion without replacing the rest of it. Concentrated potassium, high-dose vitamin C and added phosphate are three loads a slowing kidney can struggle with; food potassium and magnesium need their own measured context. The video sorts familiar bottles into stop, keep and watch, and explains why a short illness can change the decision.
What we cover
How high-potassium readings became more common as kidney-disease stage advanced in a Danish record review, and why this is an association. Primary source
Concentrated potassium in pills, salt substitutes and powders, and the difference between a supplement and potassium in ordinary food. Primary source
High-dose vitamin C: 1 gram daily for three days raised urine oxalate in calcium-stone formers. Primary source
Where multivitamins, fish oil, vitamin D, protein powder and creatine land, and why creatine can complicate a creatinine-based kidney estimate. Primary source
Why magnesium should be measured rather than automatically stopped: low magnesium was common in a large predialysis cohort, while dose and clearance still matter. Primary source
Added phosphate in the other-ingredients line, and why a clinician-agreed sick-day plan belongs beside the supplement list. Consensus
Timestamps
00:00 Why the same supplement bottle behaves differently
01:01 Potassium, oxalate and added phosphate
01:39 eGFR: your filtering number
04:10 Concentrated potassium: pills, salt substitutes and powders
05:30 High-dose vitamin C and oxalate
06:53 Multivitamins, fish oil, vitamin D, protein powder and creatine
09:05 Potassium from food versus supplements
10:26 Magnesium: dose and kidney function matter
12:16 Finding added phosphate on labels
13:33 Make a sick-day plan with your clinician
References
Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes, a Danish population-based cohort study. Nephrology Dialysis Transplantation. 2018;33(9):1610-1620. PMID 29177463. https://doi.org/10.1093/ndt/gfx312
High-potassium readings rose with kidney-disease stage; potassium-supplement use was associated with higher prevalence, not proven to cause it. Evidence type: observational cohort.
Baxmann AC, De O G Mendonca C, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney International. 2003;63(3):1066-1071. PMID 12631089. https://doi.org/10.1046/j.1523-1755.2003.00815.x
One gram of vitamin C daily for three days increased urinary oxalate in stone formers. Evidence type: short intervention study.
Tsiaras A, Loufopoulos G, Theodoridis X, Liakopoulos V, Poulia KA, Chourdakis M. The effect of creatine supplementation on kidney function: a systematic review and meta-analysis of randomized controlled trials. Journal of Renal Nutrition. 2026. PMID 42035842. https://doi.org/10.1053/j.jrn.2026.04.010
Creatine raised serum creatinine without a significant difference in estimated GFR in the pooled trials. Evidence type: systematic review and meta-analysis.
Ramos CI, Gonzalez-Ortiz A, Espinosa-Cuevas A, et al. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrology Dialysis Transplantation. 2021;36(11):2049-2057. PMID 33247727. https://doi.org/10.1093/ndt/gfaa232
Dietary potassium was not associated with blood potassium in 95 people with nondialysis kidney disease. Evidence type: observational study.
Oka T, Hamano T, Sakaguchi Y, et al. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia: a common electrolyte abnormality in chronic kidney disease. Nephrology Dialysis Transplantation. 2019;34(7):1154-1162. PMID 29796601. https://doi.org/10.1093/ndt/gfy119
Low magnesium was common in predialysis CKD and associated with proteinuria-related magnesium wasting. Evidence type: observational study.
Vermeulen EA, Vervloet MG. Magnesium administration in chronic kidney disease. Nutrients. 2023;15(3):547. PMID 36771254. https://doi.org/10.3390/nu15030547
Reviews magnesium administration and the relevance of kidney clearance and monitoring. Evidence type: narrative review.
Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2010;5(3):519-530. PMID 20093346. https://doi.org/10.2215/CJN.06080809
Explains the greater absorption of added inorganic phosphate compared with phosphorus naturally bound in plant foods. Evidence type: narrative review.
Watson KE, Dhaliwal K, Robertshaw S, et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. American Journal of Kidney Diseases. 2023;81(5):564-574. PMID 36470530. https://doi.org/10.1053/j.ajkd.2022.10.012
A multidisciplinary panel developed medication sick-day guidance; an equivalent tested supplement protocol was not established. Evidence type: expert consensus.
Disclosure: two authors of the Danish potassium study were employed by AstraZeneca.
One study explained in plain language every week, with sources attached, plus the free kidney health guide: https://guides.selfprinciple.org/kidney
This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Sean Hashmi's own and do not represent his employer.
Never start, stop, or change the dose of any prescription medication without consulting your physician.
Comments